Why the study?
Do ERβ agonists like OSU-ERb-012 modulate T-lymphocyte activation and ameliorate left ventricular remodeling during chronic heart failure?
Do ERβ agonists like OSU-ERb-012 modulate T-lymphocyte activation and ameliorate left ventricular remodeling during chronic heart failure?
ERβ agonists such as OSU-ERb-012 show potential as selective immunomodulatory therapies to attenuate adverse left ventricular remodeling in chronic heart failure.
Answers are grounded in this paper and cite their sources.
ERβ agonists are hypothesis-generating for T-cell immunomodulation in HF; prospective human trials needed before clinical adoption.
Our studies indicate that ERβ agonists and OSU-ERb-012, in particular, could be used as selective immunomodulatory drugs to inhibit CD4⁺ T cells during chronic HF.
No takes yet. Share an insight, caveat, or question.
Rosenzweig et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: